FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

March 12, 2020

Press Releases

Comments Off on FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections

— Three Clinical Sites to Enroll Patients with Recurrent and Complicated Urinary Tract Infections — March 12, 2020 10:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and […]

Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

February 10, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program

–Company is Recognized Top 1% among 4,000 applicants from 133 Countries– February 10, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the company has been selected to participate […]

Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

January 8, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense

Funds Designated to Support Clinical Development of PhageBankTM Precision Bacteriophage Therapeutic January 08, 2020 10:00 AM Eastern Standard Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced the Department of Defense (DoD) has awarded APT a contract of […]

Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

October 30, 2019

Press Releases

Comments Off on Adaptive Phage Therapeutics to Present to Investors at 2019 World Antimicrobial Resistance Congress

–CEO to Outline Vision at Global Gathering of Infectious Disease Leaders and Investors– October 30, 2019 08:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that Greg Merril, CEO and co-founder […]

Lung Transplant Patient with Antibiotic Resistant Bacterial Infection Successfully Treated with Bacteriophage

April 5, 2018

Press Releases

Comments Off on Lung Transplant Patient with Antibiotic Resistant Bacterial Infection Successfully Treated with Bacteriophage

April 05, 2018 01:31 PM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Today, Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, announced the first report of bacteriophage (phage) therapy in treating bacterial infection in a lung transplant patient. The 67 year-old male patient, […]

Terminally Ill Patient Successfully Treated with Bacteriophage

April 26, 2017

Press Releases

Comments Off on Terminally Ill Patient Successfully Treated with Bacteriophage

April 26, 2017 07:07 PM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Today, Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, announced that a therapeutic approach leveraging bacteriophage (phage), as outlined in 2003 by NIH Emeritus Scientist, Carl R Merril, MD, (Merril, et al, Nature Reviews; […]